Newspatrolling.com News cum Content Syndication Portal Online
SINGAPORE –
Media OutReach Newswire – 1 August 2024 – A white paper released by the Lung Cancer Education and Advocacy for Patients (LEAP) has highlighted the importance of enhancing patient advocacy in lung cancer, alongside key challenges and opportunities in this space in Singapore. The report, titled
Empowering Asian Lung Cancer Advocates, draws on global best practices as well as insights from the Hopeful Voices Patient Advocate Roundtable Meeting, hosted by Lung Cancer Education and Advocacy for Patients (LEAP) and the Lung Cancer Consortium Singapore (LCCS) in late 2023.
During roundtable discussions attended by lung cancer patients and their families, several key priorities in the lung cancer care continuum were identified:
1. Increasing the influence of patient advocates in decision-making and healthcare service development
2. Improving early-stage lung cancer diagnoses by raising awareness or improving access to early screening.
3. Improving access to innovative treatments and diagnostics.
Lung cancer remains the most frequently diagnosed cancer worldwide, representing about 12.4% of all cases in 2022. It is the primary cause of cancer-related deaths globally, with over 1.8 million fatalities annually[1]. In Singapore, it is the third most common cancer and leading cause of cancer deaths[2]. With ageing populations in Asia, more people are expected to be diagnosed with cancer. Inevitably, they and their caregivers, as well as their healthcare teams may encounter challenges across the cancer care continuum, including education, screening, diagnosis, treatment, survivorship, rehabilitation, and end-of-life care[3].
Dr Teh Yi Lin, Medical Oncologist and Lead for LEAP said, “Robust support services, such as medical treatment support, psychosocial care, and educational resources, are essential to ensure that lung cancer patients and their loved ones are well-informed and supported. Patient advocates play a pivotal role in helping to ensure that there is effective support for those affected by cancer.”
The white paper outlines actionable recommendations for patient advocacy groups to address the issued identified and enhance lung cancer advocacy in Singapore. They include:
1. Enhancing patient advocacy for better cancer care
Foster empowered communities: Build and support communities that provide evidence-based information, psychosocial support, and financial guidance to help patients and families manage the complexities of their cancer journey
Utilise social networks and media platforms for engagement: Develop and leverage social media and traditional media platforms to connect patients and advocates, enabling them to share experiences, personal stories and advice to raise public awareness.
Integrate patient insights in research: Collaborate with researchers to integrate patient needs and perspectives in clinical trials and studies
Advocacy training and mentorship: Offer training and mentorship programs to equip individuals with the skills needed for effective advocacy
2. Advocate for better access to lung cancer screening
Increase public awareness and participation: Implement broad education campaigns and community outreach to increase awareness of lung cancer risks and the benefits of early screening.
Policy advocacy for screening access: Establish strong partnerships between patient advocacy groups, scientists, and policy-makers to keep up-to-date with the latest scientific findings on the importance of lung cancer screening.
3. Advocate for better access to potentially life-saving treatments and clinical trials
Raise public awareness and educate patients: Collaborate with healthcare professionals to inform patients about the availability of new treatments and companion diagnostic tests to improve early detection and diagnosis.
Lower financial barriers: Work towards ensuring access to treatments and diagnostic tests and reducing the financial burden on patients.
Facilitate clinical trial participation: Increase public and patient education on the benefits of participating in clinical trials.
The white paper is supported by AstraZeneca. For more information and to download the full white paper, please visit
[1] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024.
[2] Ferlay J EM, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from:
https://gco.iarc.who.int/today.
Hashtag: #LEAP #lungcancer #patientadvocacy
The issuer is solely responsible for the content of this announcement.